|Table of Contents|

Efficacy and safety of anlotinib plus PD-1 blockade for third-line or further-line treatment of advanced non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3024-3027
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of anlotinib plus PD-1 blockade for third-line or further-line treatment of advanced non-small cell lung cancer
Author(s):
PAN Xiaoting; DAI Anwei
Department of Oncology,Traditional Chinese Medicine Hospital of Kunshan,Jiangsu Suzhou 215300,China.
Keywords:
anlotinib; advanced non-small cell lung cancer; PD-1 blockade; retrospective study
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.16.014
Abstract:
Objective:To investigate the efficacy and safety of anlotinib plus PD-1 blockade for third-line or further-line treatment of advanced non-small cell lung cancer (NSCLC).Methods：Advanced NSCLC patients who received anlotinib plus PD-1 blockade for third-line or further-line treatment at department of oncology of our hospital were selected between January 1,2020 and December 31,2021.The primary end points were progression free survival (PFS) and overall survival (OS).The secondary end points were objective response rate (ORR) and disease control rate (DCR).The safety of the combination treatment was assessed by the incidence of adverse events.Results:In the 62 advanced NSCLC patients who received anlotinib plus PD-1 blockade for third-line or further-line treatment,8 patients achieved partial response (PR).The median PFS was 6.4 months (95%CI:5.4~7.4 months) and the median OS was 15.4 months (95%CI:13.4~17.4 months).During the treatment,the most common adverse events were fatigue,loss of appetite,hypertension and hand-foot syndrome and the most severe adverse event was hyperthyroidism.Conclusion:The combination of anlotinib and PD-1 blockade for third-line or further-line treatment has promising efficacy for the advanced NSCLC patients and the toxicity is tolerable.

References:

[1]NARJUST D,RAFAEL SD,JULAIN RM.Non-small cell lung cancer:epidemiology,screening,diagnosis,and treatment［J］.Mayo Clin Proc,2019,94(8):1623-1640.
[2]ALEXANDER M,KIM SY,CHENG HY.Update 2020:management of non-small cell lung cancer［J］.Lung,2020,198(6):897-907.
[3]RAMALINGAM SS,VANSTEENKISTE J,PLANCHARD D,et al.Overall survival with osimertinib in untreated,EGFR-mutated advanced NSCLC［J］.N Engl J Med,2020,382(1):41-50.
[4]SALOUS T,SHUKLA NA,ALTHOUSE SK,et al.A phase 2 trail of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD -1 or PD -L1 inhibitor:big ten cancer research consortium BTCRC-LUN15-029［J］.Cancer,2023,129(2):264-271.
[5]GIGLIO AD,FEDERICO AD,NUVOLA G,et al.The landscape of immunotherapy in advanced NSCLC:driving beyond PD-1/PD-L1 inhibitors(CTLA-4,LAG3,IDO,OX40,TIGIT,Vaccines)［J］.Curr Oncol Rep,2021,23(11):126.
[6]NADAL E,MASSUTI B,DOMINE M,et al.Immunotherapy with checkpoint inhibitors in non-small cell lung cancer:insights from long-term survivors［J］.Cancer Immunol Immunother,2019,68(3):341-352.
[7]KIM JY,LEE KH,KANG J,et al.Hyperprogressive disease during anti-PD-1 (PDCD1) / PD-L1 (CD274) therapy:a systematic review and meta-analysis［J］.Cancers (Basel),2019,11(11):1699.
[8]LIU S,QIN T,LIU Z,et al.Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells［J］.Cell Death Dis,2020,11(5):309.
[9]YANG Y,LI L,JIANG Z,et al.Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer［J］.Cancer Immunol Immunother,2020,69(12):2523-2532.
[10]HAN B,LI K,WANG Q,et al.Effect of anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer:the ALTER 0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018,4(11):1569-1575.
[11]LEE WS,YANG H,CHON HJ,et al.Combination of therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity［J］.Exp Mol Med,2020,52(9):1475-1485.
[12]SU YD,LUO BY,LU Y,et al.Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma［J］.Clin Cancer Res,2022,28(4):793-809.
[13]CAI XM,WEI B,LI LL,et al.Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression［J］.Int Immunopharmacol,2020,88:106858.
[14]XIONG Q,QIN BY,XIN LL,et al.Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer［J］.Frontiers in Oncology,2021,11:659380.
[15]LIAN ZZ,DU WW,ZHANG Y,et al.Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation［J］.Thorac Cancer,2020,11:1934-1943.
[16]HU HY,LIU YY,TAN ST,et al.Anlotinib exerts anti-cancer effects on KRAS-mutated lung cancer cell through suppressing the MEK/ERK pathway［J］.Cancer Manag Res,2020,12:3579-3587.
[17]YIN JQ,WU YJ,YANG X,et al.Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer:occurrence and mechanism［J］.Front Immunol,2022,13:830631.
[18]NIGRO O,PINOTTI G,DE GALITIIS F,et al.Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors:a multicentre study［J］.Eur J Cancer,2020,134:19-28.

Memo

Memo:
-
Last Update: 1900-01-01